Zu den Inhalten springen
Universitäts-Herzzentrum Freiburg - Bad KrozingenUniversitäts-Herzzentrum Freiburg - Bad Krozingen

Publications

Link pubmed

Original, first-authored

Olivier CB, Middleton SK, Purington N, Shashidhar S, Hereford J, Mahaffey KW, Turakhia MP. Why digital health trials can fail: Lessons learned from a randomized trial of health coaching and virtual cardiac rehabilitation
Cardiovascular Digital Health Journal (JCR 2020 IF N/P)

Olivier CB, Sundaram V, Chertow G, Shashidhar S, McDonnell K, Ding V, Desai M, Mahaffey KW, Mell M.
A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation
J Vasc Access. 2020 Jul;21(4):467-474.
(JCR 2018: IF 1.4)

Olivier CB, Fan J, Askari M, Mahaffey KW, Heidenreich PA, Perino AC, Leef GC, Ho PM, Harrington RA, Turakhia MP;
Site Variation and Outcomes for Antithrombotic Therapy in AF Patients after PCI: Findings from the Veterans Health Administration
Circ Cardiovasc Interv. 2019 Aug;12(8):e007604. (JCR 2018: IF 6.1)

Olivier CB, Bhatt DL, Leonardi S, Stone GW, Gibson CM, Steg PG, Hamm CW, Wilson MD, Mangum S, Price MJ, Prats J, White HD, Lopes RD, Harrington RA, Mahaffey KW;
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results From CHAMPION PHOENIX
Circ Cardiovasc Interv
. 2019 Jul;12(7):e007342. (JCR 2018: IF 6.1)

Olivier CB, Mulder H, Hiatt WR, Jones WS, Fowkes FGR, Rockhold FW, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster J, Patel MR, Mahaffey KW.
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial
JAMA Cardiol. 2019 Jan 1;4(1):7-15. (JCR 2018: IF 11.9)

Olivier CB, Sundaram V, Bhatt DL, Leonardi S, Lopes RD, Ding VY, Yang L, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, White HD, Desai M, Lynch DR., Harrington RA, Mahaffey KW.
Definitions of Peri-Procedural Myocardial Infarction and the Association with One-Year Mortality: Insights from CHAMPION Trials
Int J Cardiol. 2018 Nov 1;270:96-101 (JCR 2016: IF 6.2)

Olivier CB, Weik P, Meyer M, Weber S, Diehl P, Bode C, Moser M, Zhou Q.
Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors
J Thromb Thrombolysis.
2016 Aug;42(2):161-6 (JCR 2014: IF 2.2)

Olivier CB, Meyer M, Bauer H, Schnabel K, Weik P, Zhou Q, Bode C, Moser M, Diehl P.
The ratio of ADP- to TRAP-induced platelet aggregation quantifies P2Y12-dependent platelet inhibition independently of the platelet count
PLoS One. 2016 Feb 17;11(2):e0149053.
(JCR 2014: IF 3.2)

Olivier CB, Schnabel K, Weber S, Zhou Q, Bode C, Moser M, Diehl P.
Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on bodyweight in contrast to clopidogrel
J Thromb Thrombolysis. 2016 Jul;42(1):84-9. (JCR 2014: IF 2.2)

Olivier CB, Weik P, Meyer M, Weber S, Anto-Michel N, Diehl P, Zhou Q, Geisen U, Bode C, Moser M.
TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
Thromb Res. 2016 Feb;138:63-8. (JCR 2014: IF 2.4)

Olivier CB, Schnabel K, Brandt C, Weik P, Olschewski M, Zhou Q, Bode C, Diehl P, Moser M.
A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone.
Clin Res Cardiol. 2014 Dec;103(12):968-75. (JCR 2013: IF 4.2)

Olivier CB, Diehl P, Schnabel K, Weik P, Zhou Q; Bode C, Moser M.
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Thromb Haemost. 2014 Feb;111(2):266-72. (JCR 2012: IF 6.1)

Original, last-authored

Heger LA, Danzer M, Bode C, Hortmann M, Duerschmied D, Olivier CB* and Moser M*; *equally contributed
Dual-pathway antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention in stable coronary artery disease: A single-centre, single operator, retrospective cohort study
Front Med (Lausanne). 2020 Sep 30;7:414. (JCR 2020: 3.1)

Rilinger J, Meyer M, Schnabel K, Weik P, Charlet A, Esser J, Zhou Q, Bode C, Moser M, Diehl P, Olivier CB.
High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting.
J Thromb Thrombolysis. 2016 Nov;42(4):558-65. (JCR 2014: IF 2.2)

Original, co-authored

Rieder M, Laumann R, Witsch T, Schanze N, Heger L, Olivier CB, Muehlen C, Bode C, Ahrens I, Lother A, Duerschmied D, Hortmann M.
Evaluation of serum serotonin as a biomarker for myocardial infarction and ischemia/reperfusion injury
Appl. Sci. 2020, 10(18), 6379

Leef GC, Perino AC, Askari M, Fan J, Ho PM, Olivier CB, Longo L, Mahaffey KW, Turakhia MP.
Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration.
J Pharm Pract. 2020 Oct;33(5):647-653.

Yong CM, Sundaram V, Abnousi F, Olivier CB, Yang J, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Deliargyris E, Prats J, White HD, Harrington RA, Bhatt DL, Mahaffey KW.
The Efficacy and Safety of Cangrelor in Single Vessel versus Multi Vessel Percutaneous Coronary Intervention: Insights from CHAMPION PHOENIX.
Clin Cardiol. 2019 Jun 29;42(9):797-805 (JCR 2018: IF 2.5)

Rilinger J, Heilmann C, Beitinger U, Olivier CB, Diehl P, Beyersdorf F, Siepe M. Moderate ischemic mitral regurgitation. Coronary artery bypass grafting with versus without simultaneous treatment of the mitral valve is associated with comparable long-term survival.
J Cardiovasc Surg (Torino). 2018 Dec;59(6):830-835 (JCR 2016: IF 2.2)

Zhou Q, Einert M, Schmitt H, Wang Z, Pankratz F, Olivier CB, Bode C, Liao JK, Moser M
MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation.
Vascul Pharmacol. 2016 Sep;84:67-73. (JCR 2014: IF 3.6)

Diehl P, Halscheid C, Olivier C, Helbing T, Bode C, Moser M.
Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation.
Clin Res Cardiol. 2011 Sep;100(9):765-71. (JCR 2010: IF 3.5)

Diehl P, Olivier C, Halscheid C, Helbing T, Bode C, Moser M.
Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Basic Res Cardiol. 2010 May;105(3):379-87. (JCR 2009: IF 6.0)

Consensus Documents or Guidelines

Hochholzer W, Nührenberg T, Flierl U, Olivier CB, Landmesser U, Möllmann H, Dörr M, Mehilli J, Schäfer A, Dürschmied D, Sibbing D, El-Armouche A, Zeymer U, Neumann FJ, Ahrens I, Geisler T. Antithrombotische Therapie nach strukturellen kardialen Interventionen
accepted for publication in Der Kardiologe

Reviews (invited)

Olivier CB, Duerschmied D, Bode C. Klinische Studien zur antithrombotischen Therapie kardiovaskulärer Erkrankungen Update 2019
Der Klinikarzt 2020; 49(03): 57-61 (IF N/P)

Olivier CB, Turakhia MP, Mahaffey KW. Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome.
Expert Opin Drug Saf. 2018 Mar;17(3):251-258. (JCR 2016: IF 3.5)

Olivier CB, Bode C, Moser M. Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention/Acute Coronary Syndrome.
Aktuel Kardiol 2017; 6(05): 367-372 (IF N/P)

Olivier CB, Bode C, Moser M.
Peri- und postinterventionelle Thrombozyten-Aggregationshemmung bei Diabetikern.
Vasomed 2015; 5: 253-254. (IF N/K)

Olivier CB, Bode C, Moser M.
Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration.
Herz. 2014 Nov;39(7):808-13. (JCR 2013: IF 0.9)

Helbing T, Olivier C, Bode C, Moser M, Diehl P.
Role of microparticles in endothelial dysfunction and arterial hypertension.
World J Cardiol. 2014 Nov 26;6(11):1135-1139. Review (IF N/K)

Moser M, Olivier CB, Bode C.
Triple antithrombotic therapy in cardiac patients: more questions than answers.
Eur Heart J. 2014 Jan;35(4):216-23. (JCR 2012: IF 14.1)

Olivier C, Diehl P, Bode C, Moser M.
Thrombin Receptor Antagonism in Antiplatelet Therapy.
Cardiol Ther (2013) 2:57–68 (IF N/P)

Editorials, Comments, and Others (invited)

Bode C, Olivier CB, Duerschmied D.
Is Bleeding Always Bad?: Bad Boy Bleeding.
J Am Coll Cardiol. 2019 Sep 24;74(12):1529-1531. (JCR 2018: IF 18.6)

Bode C, Olivier CB, Duerschmied D.
Anticoagulation and anaemia: old opponents from the era of VKA?
Eur Heart J. 2019 Aug 31. (JCR 2018: IF 23.2)

Diehl P, Olivier C, Bode C, Moser M.
Editorial comment: Reduction of oxidative stress: a new indication for acetylsalicylic acid in coronary artery bypass surgery.
Eur J Cardiothorac Surg. 2013 Jun;43(6):1163-4. (JCR 2012: IF 2.7)

 

PD Dr. Christoph Olivier

PD Dr. Christoph B. Olivier

Telefon: +49 761 270 37180
E-Mail:   christoph.olivier@
universitaets-herzzentrum.de